您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > RTI-7470-44
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
RTI-7470-44
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
RTI-7470-44图片
规格:98%
分子量:449.84
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
RTI-7470-44 是一种有效且具有选择性和血脑屏障透过性的人微量胺相关受体 1 (hTAAR1) 拮抗剂,IC50 为 8.4 nM。RTI-7470-44 具有中等的代谢稳定性和良好的初步脱靶谱。RTI-7470-44 可增加小鼠中脑腹侧被盖区 (VTA) 多巴胺能神经元的自发放电率。RTI-7470-44 可用于精神分裂症、药物成瘾和帕金森病 (PD) 的研究。
货号:ajcx39058
CAS:825658-63-7
分子式:C19H11ClF3N5OS
分子量:449.84
溶解度:DMSO : 20.83 mg/mL (46.31 mM; ultrasonic and warming and heat to 60°C)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

RTI-7470-44 is a potent, selective and blood-brain barrier (BBB) penetrant human trace amine-associated receptor subtype 1 (hTAAR1) antagonist with an IC50 value of 8.4 nM and a Ki value of 0.3 nM. RTI-7470-44 has moderate metabolic stability, and a favorable preliminary off-target profile. RTI-7470-44 can increase the spontaneous firing rate of mouse ventral tegmental area (VTA) dopaminergic neurons. RTI-7470-44 can be used for researching schizophrenia, drug addiction, and Parkinson's disease (PD)[1].

RTI-7470-44 (10 μM) shows little to no off-target activity with the exception of the benzylpiperazine (BZP) rat brain site and human sigma 2 with inhibition of 75 and 90%, respectively; has a moderate affinity for the BZP rat brain site (Ki=1 μM) and a very weak affinity for human sigma 2 (Ki=8.4 μM)[1].

RTI-7470-44 (40 μM) significantly increases the firing rate of dopaminergic neurons in VTA slices from DAT-IRES-Cre; td-Tomato mice, and reverses the inhibitory effect of RO5166017 (a TAAR1 agonist)[1].RTI-7470-44 (10 μM) has decent stability in human liver microsomes, less stable in mouse liver microsomes and very poor stability in rat liver microsomes[1].Stability of RTI-7470-44 in Human, Rat, and Mouse Liver Microsomes[1].
species half-life (min) clearance, CLINT (mL/min/mg) Human83.914.9Rat9.11274Mouse65.863.5

[1]. Decker AM, et al. Identification of a Potent Human Trace Amine-Associated Receptor 1 Antagonist. ACS Chem Neurosci. 2022 Apr 6;13(7):1082-1095.